These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 27706215)
21. Metabolic correlates of levodopa response in Parkinson's disease. Feigin A; Fukuda M; Dhawan V; Przedborski S; Jackson-Lewis V; Mentis MJ; Moeller JR; Eidelberg D Neurology; 2001 Dec; 57(11):2083-8. PubMed ID: 11739830 [TBL] [Abstract][Full Text] [Related]
22. Effects of levodopa therapy on voxel-based degree centrality in Parkinson's disease. Zhong M; Yang W; Huang B; Jiang W; Zhang X; Liu X; Wang L; Wang J; Zhao L; Zhang Y; Liu Y; Lin J; Huang R Brain Imaging Behav; 2019 Oct; 13(5):1202-1219. PubMed ID: 30091020 [TBL] [Abstract][Full Text] [Related]
23. Assessing dopaminergic function in Parkinson's disease: levodopa kinetic-dynamic modeling and SPECT. Contin M; Martinelli P; Riva R; Dondi M; Fanti S; Pettinato C; Scaglione C; Albani F; Baruzzi A J Neurol; 2003 Dec; 250(12):1475-81. PubMed ID: 14673582 [TBL] [Abstract][Full Text] [Related]
24. A comparison of inhomogeneous magnetization transfer, myelin volume fraction, and diffusion tensor imaging measures in healthy children. Geeraert BL; Lebel RM; Mah AC; Deoni SC; Alsop DC; Varma G; Lebel C Neuroimage; 2018 Nov; 182():343-350. PubMed ID: 28916179 [TBL] [Abstract][Full Text] [Related]
25. Integrated robotics platform with haptic control differentiates subjects with Parkinson's disease from controls and quantifies the motor effects of levodopa. Gaprielian P; Scott SH; Lowrey C; Reid S; Pari G; Levy R J Neuroeng Rehabil; 2019 Oct; 16(1):124. PubMed ID: 31655612 [TBL] [Abstract][Full Text] [Related]
26. Regional volumetric change in Parkinson's disease with cognitive decline. Gee M; Dukart J; Draganski B; Wayne Martin WR; Emery D; Camicioli R J Neurol Sci; 2017 Feb; 373():88-94. PubMed ID: 28131236 [TBL] [Abstract][Full Text] [Related]
27. Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease. Lee SH; Lee MJ; Lyoo CH; Cho H; Lee MS J Neural Transm (Vienna); 2018 Sep; 125(9):1333-1339. PubMed ID: 29971496 [TBL] [Abstract][Full Text] [Related]
28. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Goetz CG; Stebbins GT; Blasucci LM Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412 [TBL] [Abstract][Full Text] [Related]
29. Integrated PET/MRI With Wu Y; Xu XJ; Sun X; Zhai H; Wang T; Cao XB; Xu Y Behav Brain Res; 2023 Oct; 454():114609. PubMed ID: 37532003 [TBL] [Abstract][Full Text] [Related]
30. Levodopa responsiveness and white matter alterations in Parkinson's disease: A DTI-based study and brain network analysis: A cross-sectional study. Du J; Zhou X; Liang Y; Zhao L; Dai C; Zhong Y; Liu H; Liu G; Mo L; Tan C; Liu X; Chen L Brain Behav; 2022 Dec; 12(12):e2825. PubMed ID: 36423257 [TBL] [Abstract][Full Text] [Related]
31. Sex effects on brain structure in de novo Parkinson's disease: a multimodal neuroimaging study. Tremblay C; Abbasi N; Zeighami Y; Yau Y; Dadar M; Rahayel S; Dagher A Brain; 2020 Oct; 143(10):3052-3066. PubMed ID: 32980872 [TBL] [Abstract][Full Text] [Related]
32. Amplitude of low-frequency oscillations in Parkinson's disease: a 2-year longitudinal resting-state functional magnetic resonance imaging study. Hu XF; Zhang JQ; Jiang XM; Zhou CY; Wei LQ; Yin XT; Li J; Zhang YL; Wang J Chin Med J (Engl); 2015 Mar; 128(5):593-601. PubMed ID: 25698189 [TBL] [Abstract][Full Text] [Related]
33. Influence of white matter MRI hyper-intensities on acute l-dopa response in patients with Parkinson's disease. Arena JE; Cerquetti D; Rossi M; Chaves H; Rollan C; Dossi DE; Merello M Parkinsonism Relat Disord; 2016 Mar; 24():126-8. PubMed ID: 26823237 [TBL] [Abstract][Full Text] [Related]
34. Microstructural and functional alterations of the ventral pallidum are associated with levodopa-induced dyskinesia in Parkinson's disease. Gan Y; Su D; Zhang Z; Zhang Z; Yan R; Liu Z; Wang Z; Zhou J; Lam JST; Wu T; Jing J; Feng T Eur J Neurol; 2024 Feb; 31(2):e16147. PubMed ID: 37975786 [TBL] [Abstract][Full Text] [Related]
35. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
36. The relationship between depression and regional cerebral blood flow in Parkinson's disease and the effect of selegiline treatment. Imamura K; Okayasu N; Nagatsu T Acta Neurol Scand; 2011 Jul; 124(1):28-39. PubMed ID: 20880269 [TBL] [Abstract][Full Text] [Related]
38. Levodopa Reduces the Phase lag Index of Parkinson's Disease Patients: A Magnetoencephalographic Study. Cao C; Li D; Zeng K; Zhan S; Huang P; Li X; Sun B Clin EEG Neurosci; 2019 Mar; 50(2):134-140. PubMed ID: 29914268 [No Abstract] [Full Text] [Related]
39. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia. Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733 [TBL] [Abstract][Full Text] [Related]
40. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease. Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]